Santé

Références bibliographiques

Dossier - Vers un nouveau traitement du cancer et des maladies génétiques
DossierClassé sous :génétique , traduction , amynoglycosides

-

Actuellement la plupart des maladies génétiques sont incurables. En 2000 puis plus récemment en juin 2002, la thérapie génétique a permis de soigner des "bébés bulles". Cependant ces protocoles ont récemment été arrétés suite à l'apparition chez un des enfants traités d'une leucémie, liée à l'intégration du transgène dans un gène suppresseur de tumeur. Ce problème souligne la difficulté de mettre au point une technique efficace et sure de thérapie génique. Ce dossier aborde la possibilité d'utiliser une autre approche thérapeutique afin de soigner ou de réduire les effets d'un nombre important de maladies génétiques et de cancers.

  
DossiersVers un nouveau traitement du cancer et des maladies génétiques
 

1. Mueller PP, Hinnebusch AG: Multiple Upstream AUG Codons Mediate Translational Control OF GCN4. Cell 1986, 45:201-207.
2. Yun DF, Laz TM, Clements JM, Sherman F: mRNA sequences influencing translation and the selection of AUG initiator codons in th yeast Saccharomyces cerevisiae. mol. microbiol 1996, 19:1225-1239.
3. Ivanov IP, Simin K, Letsou A, Atkins JF, Gesteland RF: The Drosophila gene for antizyme requires ribosomal frameshifting for expression and contains an intronic gene for snRNP Sm D3 on the opposite strand. Mol Cell Biol 1998, 18:1553-1561.
4. Major LL, Poole ES, Dalphin ME, Mannering SA, Tate WP: Is the in-frame termination signal of the Escherichia coli release factor-2 frameshift site weakened by a particularly poor context? Nucleic Acids Res 1996, 24:2673-2678.
5. Namy O, Duchateau-Nguyen G, Rousset JP: Translational readthrough of the PDE2 stop codon modulates cAMP levels in Saccharomyces cerevisiae. Mol Microbiol 2002, 43:641-652.
6. Zavialov AV, Buckingham RH, Ehrenberg M: A posttermination ribosomal complex is the guanine nucleotide exchange factor for peptide release factor RF3. Cell 2001, 107:115-124.
7. Brown CM, Stockwell PA, Trotman CN, Tate WP: Sequence analysis suggests that tetra-nucleotides signal the termination of protein synthesis in eukaryotes. Nucleic Acids Res 1990, 18:6339-6345.
8. Namy O, Hatin I, Rousset JP: Impact of the six nucleotides downstream of the stop codon on translation termination. EMBO Rep 2001, 2:787-793.
9. Skuzeski JM, Nichols LM, Gesteland RF, Atkins JF: The signal for a leaky UAG stop codon in several plant viruses includes the two downstream codons. J Mol Biol 1991, 218:365-373.
10. Eustice DC, Wilhelm JM: Fidelity of the eukaryotic codon-anticodon interaction: interference by aminoglycoside antibiotics. Biochemistry 1984, 23:1462-1467.
11. Howard M, Frizzell RA, Bedwell DM: Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996, 2:467-469.
12. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, Sorscher EJ: Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997, 3:1280-1284.
13. Keeling KM, Bedwell DM: Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med 2002, 80:367-376.
14. Howard MT, Shirts BH, Petros LM, Flanigan KM, Gesteland RF, Atkins JF: Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann Neurol 2000, 48:164-169.
15. Krawczak M, Ball EV, Fenton I, Stenson PD, Abeysinghe S, Thomas N, Cooper DN: Human gene mutation database-a biomedical information and research resource. Hum Mutat 2000, 15:45-51.
16. Vines DJ, Warburton MJ: Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I. FEBS Lett 1999, 443:131-135.
17. Sleat DE, Sohar I, Gin RM, Lobel P: Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Europ J Paediatr Neurol 2001, 5:57-62.
18. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL: Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999, 104:375-381.
19. Clancy JP, Bebok Z, Ruiz F, King C, Jones J, Walker L, Greer H, Hong J, Wing L, Macaluso M, Lyrene R, Sorscher EJ, Bedwell DM: Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001, 163:1683-1692.
20. Wagner KR, Hamed S, Hadley DW, Gropman AL, Burstein AH, Escolar DM, Hoffman EP, Fischbeck KH: Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001, 49:706-711.
21. Thompson J, O'Connor M, Mills J, Dahlberg A: The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol 2002, 322:273.